SCHEMBL16290337

SCHEMBL16290337

Cc1cccc2c1C(=O)C(F)(F)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
GRIA1 P42261 2/20 0.37
CACNG8 Q8WXS5 2/20 0.37
HTR5A P47898 1/20 0.34
AADAT Q8N5Z0 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 2/20 0.33
CD44 P16070 1/20 0.33
ALOX12 P18054 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
AVPR1A P37288 1/20 0.32
TBXA2R P21731 1/20 0.32
EPAS1 Q99814 1/20 0.32
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29237812 0.82 CA1 (0.39) CA1CA2CA7CA9GRIA1
SCHEMBL14430321 0.79 CA1 (0.42) CA1CA2CA7CA9GRIA1
SCHEMBL29237694 0.78 CA1 (0.36) CA1CA2CA7CA9GRIA1
SCHEMBL29237696 0.78 CA1 (0.36) CA1CA2CA7CA9GRIA1
SCHEMBL16290355 0.78 CA1 (0.41) CA1CA2CA7CA9EPAS1
SCHEMBL30856849 0.76 EPAS1 (0.41) EPAS1
SCHEMBL7190214 0.73 CA1 (0.40) CA1CA2CA7CA9GRIA1
SCHEMBL12086618 0.71 KDM4E (0.37) CA1CA2CA7CA9GRIA1
SCHEMBL14940327 0.71 CA1 (0.36) CA1CA2CA7CA9GRIA1
SCHEMBL25002993 0.70 ALDH1A1 (0.45) CA1CA2CA7CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3085369-B1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN EISAI R&D MAN CO LTD (JP) 2018-04-04 EP disclosed
EP-3085369-B1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN EISAI R&D MAN CO LTD (JP) 2018-04-04 EP disclosed
EP-2865663-B1 NOVEL INDANESULFAMIDE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
EP-2865663-B1 NOVEL INDANESULFAMIDE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2017-04-05 EP disclosed
US-9610262-B2 Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-04 US disclosed
US-9610262-B2 Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-04 US disclosed
US-9610262-B2 Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-04 US disclosed
EP-3085369-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN Eisai R&D Management Co., Ltd. (JP) 2016-10-26 EP disclosed
US-20160303058-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-20 US disclosed
US-20160303058-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-10-20 US disclosed
CN-104395285-B Indanesulfonamide derivatives Sanitary Material R&D Management Co.,Ltd. (JP) 2016-04-13 CN disclosed
WO-2015093515-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN エーザイ・アール・アンド・ディー・マネジメント株式会社 2015-06-25 WO disclosed
EP-2865663-A1 NOVEL INDANESULFAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2015-04-29 EP disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
US-9018260-B2 Indanesulfamide derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-28 US disclosed
CN-104395285-A Novel indanesulfonamide derivatives EISAI R&D MAN CO LTD 2015-03-04 CN disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303058-A1 THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN NCS1, SCN1A, TST CA1 821/4885CA2 603/4885CA7 3093/4885
US-20140371319-A1 NOVEL INDANESULFAMlDE DERIVATIVES SCN1A, SCN7A, SCN2A CA1 219/4885CA2 315/4885CA7 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.